PROM1 and non-small cell lung carcinoma: Therefore, to understand and later develop such a strategy, we evaluated the efficacy of MSCs expressing TRAIL (MSC-TRAIL) to target and kill CD133+ CSCs in NSCLC using several assays related to cell proliferation and the apoptosis of both the intrinsic and extrinsic pathways.